You searched for "Diabetic"
Supporting innovative eye disease research
Newmedica is supporting research into a potential next generation treatment for diabetic retinopathy, reinforcing its commitment as an eye health champion. Working in partnership with charity Sight Research UK, the project is led by Dr Michael O’Hare and his team...New research shows the unhealthy state of access to medicine and medical devices for blind patients
Blind and partially sighted people could become ill from medicines and medical devices, because they are not being listened to when it comes to designing, prescribing and administering treatments. The Safety Gap’ report commissioned by the Patient Safety Commissioner, Prof...
AI-Based devices in national screening programmes: barriers and challenges
Diabetic retinopathy (DR) may have long-term complications and is recorded as a leading cause of blindness. National DR screening programmes have effectively reduced severe visual loss by timely detection and subsequent treatment of sight-threatening proliferative DR and diabetic macular oedema....Belfast Eye Conference 2024
by Zina Mobarak, FY1 Doctor, Manchester University Foundation Trust, UK. The Belfast Eye conference was held online over two days, aimed at anyone interested in ophthalmology and focused on delivering informative talks from specialists in various ophthalmic specialties and presenting...The next wave of AI in ophthalmology: From screening to communication
Artificial intelligence (AI) is reshaping ophthalmology, moving from research laboratories into everyday clinical care [1]. With its strong reliance on imaging and pattern recognition, ophthalmology is uniquely positioned to benefit from AI innovations. These developments range from autonomous disease screening...A life outside ophthalmology
Lloyd Paul Aiello. It was an absolute privilege to speak to Lloyd Paul Aiello, Professor of Ophthalmology, Harvard Medical School, and Vice President of Ophthalmology and Director, Beetham Eye Institute, Joslin Diabetes Center, USA. Prof Aiello is a third-generation ophthalmologist,...Eyes on Tomorrow podcast: “Desert Island Discs for ophthalmologists”
What happens when an ophthalmologist and optometrist get chatting in a pub, over a couple of pints of Guinness, about how they could create something educational and entertaining for ophthalmologists and optometrists? The answer is the Eyes on Tomorrow podcast....
VIBIM Study: One-year results of treatment of DME with aflibercept using TnE
The VIBIM study (the treat-and-extend regimen (TER) using intravitreal aflibercept in diabetic macular edema (DME) study) was designed to evaluate the efficacy of the TER using aflibercept in the management of DME for a period of two years. The authors...From the seas to OCTs, a journey from working in TV to creating teaching in ophthalmology
To relaunch our Allied Professionals section, Paul Dimmock from Gloucestershire discusses his unique role with the Gloucestershire Retinal Education Group. In Gloucestershire we have a collection of ophthalmic-targeted departments led by Professor Peter Scanlon, Clinical Director of the NHS Diabetic...Everyday diabetes medicine could treat common cause of blindness
Doctors have found that metformin, an everyday medicine for diabetes, is associated with less progression of age-related macular degeneration (AMD), the commonest cause of blindness in western countries. People with diabetes over the age of 55 years taking metformin were...
Two-year interim safety results of the 0.2ug/day FAC intravitreal implant for the treatment of DMO
This is a 24-month interim prospective observational study of 95 previously steroid challenged patients (115 eyes) receiving intravitreal 0.2ug/day fluocinolone acetaid (FAC) implant for diabetic macular oedema (DMO) treatment. The mean IOP for pre- and post- FAC implants were stable,...
